Yahoo
NasdaqCM - Delayed Quote USD

Nutriband Inc. (NTRB)

5.55 -0.02 (-0.45%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for NTRB
  • Previous Close 5.57
  • Open 5.46
  • Bid 5.35 x 100
  • Ask 8.44 x 200
  • Day's Range 5.41 - 5.79
  • 52 Week Range 2.80 - 9.19
  • Volume 13,222
  • Avg. Volume 69,764
  • Market Cap (intraday) 67.464M
  • Beta (5Y Monthly) 2.18
  • PE Ratio (TTM) --
  • EPS (TTM) -0.53
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 15.00
  • Moby Rating Neutral

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

www.nutriband.com

--

Full Time Employees

January 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NTRB
22.25%
S&P 500 (^GSPC)
7.76%

1-Year Return

NTRB
0.36%
S&P 500 (^GSPC)
9.77%

3-Year Return

NTRB
153.42%
S&P 500 (^GSPC)
68.96%

5-Year Return

NTRB
20.96%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 400.71k
Earnings --
Profit Margin 0.00%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

0
200K
400K
600K
0.0%

Analyst Insights

View More

Analyst Price Targets

15.00
15.00 Average
5.55 Current
15.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 1/22/2025
Analyst Noble Capital Markets
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 13

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -53.48%

  • Return on Equity (ttm)

    -100.75%

  • Revenue (ttm)

    1.62M

  • Net Income Avi to Common (ttm)

    -6.96M

  • Diluted EPS (ttm)

    -0.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.42M

  • Total Debt/Equity (mrq)

    4.12%

  • Levered Free Cash Flow (ttm)

    -1.41M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: